Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

In a dynamic environment, an expert shares insights into potential AI applications in the clinical research setting at OCT ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...